Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Effect of Secukinumab on Aortic Vascular Inflammation and Cardiometabolic Biomarkers After 12 Weeks of Treatment, Compared to Placebo, and up to 52 Weeks of Treatment With Secukinumab in Adult Subjects With Moderate to Severe Chronic Plaque-type Psoriasis
Brief Summary: This study evaluated the effect of secukinumab compared to placebo on aortic vascular inflammation in adult patients who have moderate to severe plaque psoriasis that is poorly controlled by current psoriasis treatments.


Options:
A: Arm Label: 10 mg Ixekizumab; Type: EXPERIMENTAL; Interventions: Biological: Ixekizumab | Arm Label: 25 mg Ixekizumab; Type: EXPERIMENTAL; Interventions: Biological: Ixekizumab | Arm Label: 75 mg Ixekizumab; Type: EXPERIMENTAL; Interventions: Biological: Ixekizumab | Arm Label: 150 mg Ixekizumab; Type: EXPERIMENTAL; Interventions: Biological: Ixekizumab | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Biological: Ixekizumab, Drug: Placebo | Arm Label: 120 mg Ixekizumab; Type: EXPERIMENTAL; Interventions: Biological: Ixekizumab | Arm Label: 80 mg Ixekizumab; Type: EXPERIMENTAL; Interventions: Biological: Ixekizumab | Intervention Type: BIOLOGICAL; Name: Ixekizumab; Assigned to Arm(s): 10 mg Ixekizumab, 120 mg Ixekizumab, 150 mg Ixekizumab, 25 mg Ixekizumab, 75 mg Ixekizumab, 80 mg Ixekizumab, Placebo | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Group A; Type: ACTIVE_COMPARATOR; Interventions: Drug: Etanercept | Arm Label: Group B; Type: EXPERIMENTAL; Interventions: Drug: Etanercept + Acitretin | Arm Label: Group C; Type: ACTIVE_COMPARATOR; Interventions: Drug: Acitretin | Intervention Type: DRUG; Name: Etanercept; Assigned to Arm(s): Group A | Intervention Type: DRUG; Name: Etanercept + Acitretin; Assigned to Arm(s): Group B | Intervention Type: DRUG; Name: Acitretin; Assigned to Arm(s): Group C
C: Arm Label: Secukinumab 150 mg load (Group 1); Type: EXPERIMENTAL; Interventions: Biological: Secukinumab | Arm Label: Secukinumab 150 mg no load (Group 2); Type: EXPERIMENTAL; Interventions: Biological: Secukinumab | Arm Label: Secukinumab 300 mg load (Group 3); Type: EXPERIMENTAL; Interventions: Biological: Secukinumab | Arm Label: Placebo arm 1 (Group 4); Type: PLACEBO_COMPARATOR; Interventions: Biological: Secukinumab | Arm Label: Placebo arm 2 (Group 4); Type: PLACEBO_COMPARATOR; Interventions: Biological: Secukinumab | Intervention Type: BIOLOGICAL; Name: Secukinumab; Assigned to Arm(s): Placebo arm 1 (Group 4), Placebo arm 2 (Group 4), Secukinumab 150 mg load (Group 1), Secukinumab 150 mg no load (Group 2), Secukinumab 300 mg load (Group 3)
D: Arm Label: Secukinumab; Type: EXPERIMENTAL; Interventions: Drug: Secukinumab 300 mg | Arm Label: Placebo then Secukinumab; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo | Intervention Type: DRUG; Name: Secukinumab 300 mg; Assigned to Arm(s): Secukinumab | Intervention Type: BIOLOGICAL; Name: Placebo; Assigned to Arm(s): Placebo then Secukinumab

Answer: D